ARS Pharmaceuticals experienced a significant decline in stock value, losing over 23% during one after-hours session following Neffy®'s failure to add any new formularies in the July 2026 payer cycle. This outcome was unexpected, as it did not align with previous executive forecasts. The incident took place in New York on July 6, 2026.